"Alzheimer" redirects here. For other uses, see Alzheimer (disambiguation)
Alzheimer's disease
Classification and external resources
Alzheimer's disease brain comparison.jpg
Comparison of a normal aged brain (left) and the brain of a person with Alzheimer's (right). Differential characteristics are pointed out.
ICD-10 G30., F00.
ICD-9 Template:ICD9, Template:ICD9
OMIM 104300
DiseasesDB 490
MedlinePlus 000760
eMedicine neuro/13
MeSH Template:Mesh2

Alzheimer's disease (AD), also known in medical literature as Alzheimer disease, is the most common form of dementia. There is no cure for the disease, which worsens as it progresses, and eventually leads to death. It was first described by German psychiatrist and neuropathologist Alois Alzheimer in 1906 and was named after him.[1] Most often, AD is diagnosed in people over 65 years of age,[2] although the less-prevalent early-onset Alzheimer's can occur much earlier. In 2006, there were 26.6 million people worldwide with AD. Alzheimer's is predicted to affect 1 in 85 people globally by 2050.[3]

Although Alzheimer's disease develops differently for every individual, there are many common symptoms.[4] Early symptoms are often mistakenly thought to be 'age-related' concerns, or manifestations of stress.[5] In the early stages, the most common symptom is difficulty in remembering recent events, known as short term memory loss. When AD is suspected, the diagnosis is usually confirmed with tests that evaluate behaviour and thinking abilities, often followed by a brain scan if available,[6] however, examination of brain tissue is required for a definitive diagnosis. As the disease advances, symptoms can include confusion, irritability, aggression, mood swings, trouble with language, and long-term memory loss. As the person declines they often withdraw from family and society.[5][7] Gradually, bodily functions are lost, ultimately leading to death.[8] Since the disease is different for each individual, predicting how it will affect the person is difficult. AD develops for an unknown and variable amount of time before becoming fully apparent, and it can progress undiagnosed for years. On average, the life expectancy following diagnosis is approximately seven years.[9] Fewer than 3% of individuals live more than 14 years after diagnosis.[10]

AD is classified as a neurodegenerative disorder. The cause and progression of the disease are not well understood; it is associated with plaques and tangles in the brain.[11] Current treatments only help with the symptoms of the disease. There are no available treatments that stop or reverse the progression of the disease. Template:As of, more than 1,000 clinical trials have been or are being conducted to test various compounds in AD.[12] Mental stimulation, exercise, and a balanced diet have been suggested as ways to delay cognitive symptoms (though not brain pathology) in healthy older individuals, but there is no conclusive evidence supporting an effect.[13]

Because AD cannot be cured and is degenerative, the affected person increasingly relies on others for assistance. The role of the main caregiver is often taken by the spouse or a close relative.[14] Alzheimer's disease is known for placing a great burden on caregivers; the pressures can be wide-ranging, involving social, psychological, physical, and economic elements of the caregiver's life.[15][16][17] In developed countries, AD is one of the most costly diseases to society.[18][19]


Template:Quote box The disease course is divided into four stages, with progressive patterns of cognitive and functional impairments.


The first symptoms are often mistakenly attributed to ageing or stress.[5] Detailed neuropsychological testing can reveal mild cognitive difficulties up to eight years before a person fulfils the clinical criteria for diagnosis of AD.[20] These early symptoms can affect the most complex daily living activities.[21] The most noticeable deficit is memory loss, which shows up as difficulty in remembering recently learned facts and inability to acquire new information.[20][22]

Subtle problems with the executive functions of attentiveness, planning, flexibility, and abstract thinking, or impairments in semantic memory (memory of meanings, and concept relationships) can also be symptomatic of the early stages of AD.[20] Apathy can be observed at this stage, and remains the most persistent neuropsychiatric symptom throughout the course of the disease.[23] Depressive symptoms, irritability and reduced awareness of subtle memory difficulties also occur commonly.[24] The preclinical stage of the disease has also been termed mild cognitive impairment,[22] but whether this term corresponds to a different diagnostic stage or identifies the first step of AD is a matter of dispute.[25]


In people with AD the increasing impairment of learning and memory eventually leads to a definitive diagnosis. In a small portion of them, difficulties with language, executive functions, perception (agnosia), or execution of movements (apraxia) are more prominent than memory problems.[26] AD does not affect all memory capacities equally. Older memories of the person's life (episodic memory), facts learned (semantic memory), and implicit memory (the memory of the body on how to do things, such as using a fork to eat) are affected to a lesser degree than new facts or memories.[27][28]

Language problems are mainly characterised by a shrinking vocabulary and decreased word fluency, which lead to a general impoverishment of oral and written language.[26][29] In this stage, the person with Alzheimer's is usually capable of communicating basic ideas adequately.[26][29][30] While performing fine motor tasks such as writing, drawing or dressing, certain movement co-ordination and planning difficulties (apraxia) may be present but they are commonly unnoticed.[26] As the disease progresses, people with AD can often continue to perform many tasks independently, but may need assistance or supervision with the most cognitively demanding activities.[26]


Progressive deterioration eventually hinders independence, with subjects being unable to perform most common activities of daily living.[26] Speech difficulties become evident due to an inability to recall vocabulary, which leads to frequent incorrect word substitutions (paraphasias). Reading and writing skills are also progressively lost.[26][30] Complex motor sequences become less coordinated as time passes and AD progresses, so the risk of falling increases.[26] During this phase, memory problems worsen, and the person may fail to recognise close relatives.[26] Long-term memory, which was previously intact, becomes impaired.[26]

Behavioural and neuropsychiatric changes become more prevalent. Common manifestations are wandering, irritability and labile affect, leading to crying, outbursts of unpremeditated aggression, or resistance to caregiving.[26] Sundowning can also appear.[31] Approximately 30% of people with AD develop illusionary misidentifications and other delusional symptoms.[26] Subjects also lose insight of their disease process and limitations (anosognosia).[26] Urinary incontinence can develop.[26] These symptoms create stress for relatives and caretakers, which can be reduced by moving the person from home care to other long-term care facilities.[26][32]


During the final stage of AD, the person is completely dependent upon caregivers.[26] Language is reduced to simple phrases or even single words, eventually leading to complete loss of speech.[26][30] Despite the loss of verbal language abilities, people can often understand and return emotional signals.[26] Although aggressiveness can still be present, extreme apathy and exhaustion are much more common results.[26] People with AD will ultimately not be able to perform even the simplest tasks without assistance.[26] Muscle mass and mobility deteriorate to the point where they are bedridden, and they lose the ability to feed themselves.[26] AD is a terminal illness, with the cause of death typically being an external factor, such as infection of pressure ulcers or pneumonia, not the disease itself.[26]


The cause for most Alzheimer's cases is still mostly unknown except for 1% to 5% of cases where genetic differences have been identified.[33] Several competing hypotheses exist trying to explain the cause of the disease:


Around 0.1% of the cases are familial forms of autosomal (not sex-linked) dominant inheritance, which usually have an onset before age 65.[34] This form of the disease is known as early onset familial Alzheimer's disease. Most of autosomal dominant familial AD can be attributed to mutations in one of three genes: those encoding amyloid precursor protein (APP) and presenilins 1 and 2.[35] Most mutations in the APP and presenilin genes increase the production of a small protein called Aβ42, which is the main component of senile plaques.[36] Some of the mutations merely alter the ratio between Aβ42 and the other major forms—e.g., Aβ40—without increasing Aβ42 levels.[36][37] This suggests that presenilin mutations can cause disease even if they lower the total amount of Aβ produced and may point to other roles of presenilin or a role for alterations in the function of APP and/or its fragments other than Aβ. There exist variants of the APP gene which are protective.[38]

Most cases of Alzheimer's disease do not exhibit autosomal-dominant inheritance and are termed sporadic AD, in which environmental and genetic differences may act as risk factors. The best known genetic risk factor is the inheritance of the ε4 allele of the apolipoprotein E (APOE).[39][40] Between 40 and 80% of people with AD possess at least one APOEε4 allele.[40] The APOEε4 allele increases the risk of the disease by three times in heterozygotes and by 15 times in homozygotes.[34] Like many human diseases, environmental effects and genetic modifiers result in incomplete penetrance. For example, certain Nigerian populations do not show the relationship between dose of APOEε4 and incidence or age-of-onset for Alzheimer's disease seen in other human populations.[41][42] While early attempts to screen up to 400 candidate genes for association with late-onset sporadic AD (LOAD) resulted in a low yield,[34][35] more recent genome-wide association studies (GWAS) turned up 13 genes (and gene clusters): CLU, PICALM, CR1, BIN1, MS4A, ABCA7, EPHA1, CD33, CD2AP, ATP5H, EXOC4, CTNNA3, RNF219.[43][44][45]

Mutations in the TREM2 gene have been associated with a 3 to 5 times higher risk of developing Alzheimer's disease.[46][47] A suggested mechanism of action is that when TREM2 is mutated, white blood cells in the brain are no longer able to control the amount of beta amyloid present.

Cholinergic hypothesisEdit

The oldest, on which most currently available drug therapies are based, is the cholinergic hypothesis,[48] which proposes that AD is caused by reduced synthesis of the neurotransmitter acetylcholine. The cholinergic hypothesis has not maintained widespread support, largely because medications intended to treat acetylcholine deficiency have not been very effective. Other cholinergic effects have also been proposed, for example, initiation of large-scale aggregation of amyloid,[49] leading to generalised neuroinflammation.[50]

Amyloid hypothesisEdit

In 1991, the amyloid hypothesis postulated that extracellular beta-amyloid (Aβ) deposits are the fundamental cause of the disease.[51][52] Support for this postulate comes from the location of the gene for the amyloid precursor protein (APP) on chromosome 21, together with the fact that people with trisomy 21 (Down Syndrome) who have an extra gene copy almost universally exhibit AD by 40 years of age.[53][54] Also, a specific isoform of apolipoprotein, APOE4, is a major genetic risk factor for AD. Whilst apolipoproteins enhance the breakdown of beta amyloid, some isoforms are not very effective at this task (such as APOE4), leading to excess amyloid buildup in the brain.[55] Further evidence comes from the finding that transgenic mice that express a mutant form of the human APP gene develop fibrillar amyloid plaques and Alzheimer's-like brain pathology with spatial learning deficits.[56]

An experimental vaccine was found to clear the amyloid plaques in early human trials, but it did not have any significant effect on dementia.[57] Researchers have been led to suspect non-plaque Aβ oligomers (aggregates of many monomers) as the primary pathogenic form of Aβ. These toxic oligomers, also referred to as amyloid-derived diffusible ligands (ADDLs), bind to a surface receptor on neurons and change the structure of the synapse, thereby disrupting neuronal communication.[58] One receptor for Aβ oligomers may be the prion protein, the same protein that has been linked to mad cow disease and the related human condition, Creutzfeldt–Jakob disease, thus potentially linking the underlying mechanism of these neurodegenerative disorders with that of Alzheimer's disease.[59]

In 2009, this theory was updated, suggesting that a close relative of the beta-amyloid protein, and not necessarily the beta-amyloid itself, may be a major culprit in the disease. The theory holds that an amyloid-related mechanism that prunes neuronal connections in the brain in the fast-growth phase of early life may be triggered by ageing-related processes in later life to cause the neuronal withering of Alzheimer's disease.[60] N-APP, a fragment of APP from the peptide's N-terminus, is adjacent to beta-amyloid and is cleaved from APP by one of the same enzymes. N-APP triggers the self-destruct pathway by binding to a neuronal receptor called death receptor 6 (DR6, also known as TNFRSF21).[60] DR6 is highly expressed in the human brain regions most affected by Alzheimer's, so it is possible that the N-APP/DR6 pathway might be hijacked in the ageing brain to cause damage. In this model, beta-amyloid plays a complementary role, by depressing synaptic function.

Tau hypothesisEdit


The tau hypothesis is the idea that tau protein abnormalities initiate the disease cascade.[52] In this model, hyperphosphorylated tau begins to pair with other threads of tau. Eventually, they form neurofibrillary tangles inside nerve cell bodies.[61] When this occurs, the microtubules disintegrate, collapsing the neuron's transport system.[62] This may result first in malfunctions in biochemical communication between neurons and later in the death of the cells.[63]

Other hypothesesEdit

Herpes simplex virus type 1 has been proposed to play a causative role in people carrying the susceptible versions of the apoE gene.[64]

Some have hypothesized that dietary copper may play a causal role.[65]

Another hypothesis asserts that the disease may be caused by age-related myelin breakdown in the brain. Iron released during myelin breakdown is hypothesised to cause further damage. Homeostatic myelin repair processes contribute to the development of proteinaceous deposits such as beta-amyloid and tau.[66][67][68]

Oxidative stress and dys-homeostasis of biometal (biology) metabolism may be significant in the formation of the pathology.[69][70][71]

AD individuals show 70% loss of locus coeruleus cells that provide norepinephrine (in addition to its neurotransmitter role) that locally diffuses from "varicosities" as an endogenous anti-inflammatory agent in the microenvironment around the neurons, glial cells, and blood vessels in the neocortex and hippocampus.[72] It has been shown that norepinephrine stimulates mouse microglia to suppress Aβ-induced production of cytokines and their phagocytosis of Aβ.[72] This suggests that degeneration of the locus ceruleus might be responsible for increased Aβ deposition in AD brains.[72]

There is tentative evidence that exposure to air pollution may be a contributing factor to the development of Alzheimer's disease.[73]


Main article: Biochemistry of Alzheimer's disease
File:Alzheimer dementia (3) presenile onset.jpg


Alzheimer's disease is characterised by loss of neurons and synapses in the cerebral cortex and certain subcortical regions. This loss results in gross atrophy of the affected regions, including degeneration in the temporal lobe and parietal lobe, and parts of the frontal cortex and cingulate gyrus.[50] Degeneration is also present in brainstem nuclei like the locus coeruleus.[74] Studies using MRI and PET have documented reductions in the size of specific brain regions in people with AD as they progressed from mild cognitive impairment to Alzheimer's disease, and in comparison with similar images from healthy older adults.[75][76]

Both amyloid plaques and neurofibrillary tangles are clearly visible by microscopy in brains of those afflicted by AD.[11] Plaques are dense, mostly insoluble deposits of beta-amyloid peptide and cellular material outside and around neurons. Tangles (neurofibrillary tangles) are aggregates of the microtubule-associated protein tau which has become hyperphosphorylated and accumulate inside the cells themselves. Although many older individuals develop some plaques and tangles as a consequence of ageing, the brains of people with AD have a greater number of them in specific brain regions such as the temporal lobe.[77] Lewy bodies are not rare in the brains of people with AD.[78]


<div class="thumb tright" style="width:Expression error: Unrecognised punctuation character "{".px;">

<div style="float:left;margin:1px;width:Expression error: Unrecognised punctuation character "{".px;">
<div style="float:left;margin:1px;width:Expression error: Unrecognised punctuation character "{".px;"></div> <div style="float:left;margin:1px;width:Expression error: Unrecognised punctuation character "{".px;"></div>
Enzymes act on the APP (amyloid precursor protein) and cut it into fragments. The beta-amyloid fragment is crucial in the formation of senile plaques in AD.

Alzheimer's disease has been identified as a protein misfolding disease (proteopathy), caused by plaque accumulation of abnormally folded beta amyloid and tau amyloid proteins in the brain.[79] Plaques are made up of small peptides, 39–43 amino acids in length, called beta-amyloid (Aβ). Beta-amyloid is a fragment from a larger protein called amyloid precursor protein (APP), a transmembrane protein that penetrates through the neuron's membrane. APP is critical to neuron growth, survival and post-injury repair.[80][81] In Alzheimer's disease, an unknown process causes APP to be divided into smaller fragments by enzymes through proteolysis.[82] One of these fragments gives rise to fibrils of beta-amyloid, which form clumps that deposit outside neurons in dense formations known as senile plaques.[11][83]

AD is also considered a tauopathy due to abnormal aggregation of the tau protein. Every neuron has a cytoskeleton, an internal support structure partly made up of structures called microtubules. These microtubules act like tracks, guiding nutrients and molecules from the body of the cell to the ends of the axon and back. A protein called tau stabilises the microtubules when phosphorylated, and is therefore called a microtubule-associated protein. In AD, tau undergoes chemical changes, becoming hyperphosphorylated; it then begins to pair with other threads, creating neurofibrillary tangles and disintegrating the neuron's transport system.[84]

Disease mechanismEdit

Exactly how disturbances of production and aggregation of the beta-amyloid peptide gives rise to the pathology of AD is not known.[85][86] The amyloid hypothesis traditionally points to the accumulation of beta-amyloid peptides as the central event triggering neuron degeneration. Accumulation of aggregated amyloid fibrils, which are believed to be the toxic form of the protein responsible for disrupting the cell's calcium ion homeostasis, induces programmed cell death (apoptosis).[87] It is also known that Aβ selectively builds up in the mitochondria in the cells of Alzheimer's-affected brains, and it also inhibits certain enzyme functions and the utilisation of glucose by neurons.[88]

Various inflammatory processes and cytokines may also have a role in the pathology of Alzheimer's disease. Inflammation is a general marker of tissue damage in any disease, and may be either secondary to tissue damage in AD or a marker of an immunological response.[89]

Alterations in the distribution of different neurotrophic factors and in the expression of their receptors such as the brain-derived neurotrophic factor (BDNF) have been described in AD.[90][91]


File:PET Alzheimer.jpg

Alzheimer's disease is usually diagnosed based on the person's history, history from relatives, and observations of the person's behaviours. The presence of characteristic neurological and neuropsychological features and the absence of alternative conditions is supportive.[92][93] Advanced medical imaging with computed tomography (CT) or magnetic resonance imaging (MRI), and with single-photon emission computed tomography (SPECT) or positron emission tomography (PET) can be used to help exclude other cerebral pathology or subtypes of dementia.[94] Moreover, it may predict conversion from prodromal stages (mild cognitive impairment) to Alzheimer's disease.[95]

Assessment of intellectual functioning including memory testing can further characterise the state of the disease.[5] Medical organisations have created diagnostic criteria to ease and standardise the diagnostic process for practising physicians. The diagnosis can be confirmed with very high accuracy post-mortem when brain material is available and can be examined histologically.[96]


The National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and the Alzheimer's Disease and Related Disorders Association (ADRDA, now known as the Alzheimer's Association) established the most commonly used NINCDS-ADRDA Alzheimer's Criteria for diagnosis in 1984,[96] extensively updated in 2007.[97] These criteria require that the presence of cognitive impairment, and a suspected dementia syndrome, be confirmed by neuropsychological testing for a clinical diagnosis of possible or probable AD. A histopathologic confirmation including a microscopic examination of brain tissue is required for a definitive diagnosis. Good statistical reliability and validity have been shown between the diagnostic criteria and definitive histopathological confirmation.[98] Eight cognitive domains are most commonly impaired in AD—memory, language, perceptual skills, attention, constructive abilities, orientation, problem solving and functional abilities. These domains are equivalent to the NINCDS-ADRDA Alzheimer's Criteria as listed in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) published by the American Psychiatric Association.[99][100]



Neuropsychological tests such as the mini–mental state examination (MMSE) are widely used to evaluate the cognitive impairments needed for diagnosis. More comprehensive test arrays are necessary for high reliability of results, particularly in the earliest stages of the disease.[101][102] Neurological examination in early AD will usually provide normal results, except for obvious cognitive impairment, which may not differ from that resulting from other diseases processes, including other causes of dementia.

Further neurological examinations are crucial in the differential diagnosis of AD and other diseases.[5] Interviews with family members are also utilised in the assessment of the disease. Caregivers can supply important information on the daily living abilities, as well as on the decrease, over time, of the person's mental function.[95] A caregiver's viewpoint is particularly important, since a person with AD is commonly unaware of his own deficits.[103] Many times, families also have difficulties in the detection of initial dementia symptoms and may not communicate accurate information to a physician.[104]

Supplemental testing provides extra information on some features of the disease or is used to rule out other diagnoses. Blood tests can identify other causes for dementia than AD[5]—causes which may, in rare cases, be reversible.[105] It is common to perform thyroid function tests, assess B12, rule out syphilis, rule out metabolic problems (including tests for kidney function, electrolyte levels and for diabetes), assess levels of heavy metals (e.g. lead, mercury) and anaemia. (See differential diagnosis for Dementia). (It is also necessary to rule out delirium).

Psychological tests for depression are employed, since depression can either be concurrent with AD (see Depression of Alzheimer disease), an early sign of cognitive impairment,[106] or even the cause.[107][108]

Early diagnosisEdit

Emphasis in Alzheimer's research has been placed on diagnosing the condition before symptoms begin.[109] A number of biochemical tests have been developed to allow for early detection. One such test involves the analysis of cerebrospinal fluid for beta-amyloid or tau proteins,[110] both total tau protein and phosphorylated tau181P protein concentrations.[111] Searching for these proteins using a spinal tap can predict the onset of Alzheimer's with a sensitivity of between 94% and 100%.[111] When used in conjunction with existing neuroimaging techniques, doctors can identify people with significant memory loss who are already developing the disease.[111]


File:Honoré Daumier 032.jpg

At present, there is no definitive evidence to support that any particular measure is effective in preventing AD.[112] Global studies of measures to prevent or delay the onset of AD have often produced inconsistent results. Epidemiological studies have proposed relationships between certain modifiable factors, such as diet, cardiovascular risk, pharmaceutical products, or intellectual activities among others, and a population's likelihood of developing AD. Only further research, including clinical trials, will reveal whether these factors can help to prevent AD.[113]


Although cardiovascular risk factors, such as hypercholesterolaemia, hypertension, diabetes, and smoking, are associated with a higher risk of onset and course of AD,[114][115] statins, which are cholesterol lowering drugs, have not been effective in preventing or improving the course of the disease.[116][117]

Long-term usage of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with a reduced likelihood of developing AD.[118] Human postmortem studies, in animal models, or in vitro investigations also support the notion that NSAIDs can reduce inflammation related to amyloid plaques.[118] However, trials investigating their use as palliative treatment have failed to show positive results, apparently because the brain NSAID concentration after an oral NSAID dose is exceedingly small.[119] No prevention trial has been completed.[118] Hormone replacement therapy, although previously used, may increase the risk of dementia.[120]


People who engage in intellectual activities such as reading, playing board games, completing crossword puzzles, playing musical instruments, or regular social interaction show a reduced risk for Alzheimer's disease.[121] This is compatible with the cognitive reserve theory, which states that some life experiences result in more efficient neural functioning providing the individual a cognitive reserve that delays the onset of dementia manifestations.[121] Education delays the onset of AD syndrome, but is not related to earlier death after diagnosis.[122] Learning a second language even later in life seems to delay getting Alzheimer disease.[123] Physical activity is also associated with a reduced risk of AD.[122]


People who eat a mediterranean diet have a lower risk of AD,[124][125] and it may improve outcomes in those with the disease.[126] Those who eat a diet high in saturated fats and simple carbohydrates have a higher risk.[127] The mediterranean diet's beneficial cardiovascular effect has been proposed as the mechanism of action.[125] There is limited evidence that light to moderate use of alcohol, particularly red wine, is associated with lower risk of AD.[128] There is tentative evidence that caffeine may be protective.[129] A number of foods high in flavonoids such as cocoa, red wine, and tea may decrease the risk of AD.[130][131]

Reviews on the use of vitamins and minerals have not found enough consistent evidence to recommend them. This includes vitamin A,[132][133] C,[134][135] E,[135][136] selenium,[137] zinc,[138] and folic acid with or without vitamin B12.[139] Additionally vitamin E is associated with health risks.[135] Trials examining folic acid (B9) and other B vitamins failed to show any significant association with cognitive decline.[140] In those already affected with AD adding docosahexaenoic acid, an Omega 3 fatty acid, to the diet has not been found to slow decline.[141]

Curcumin as of 2010 has not shown benefit in people even though there is tentative evidence in animals.[142] There is inconsistent and unconvincing evidence that ginkgo has any positive effect on cognitive impairment and dementia,[143] and a recent study concludes that it has no effect in reducing the rate of AD incidence.[144]Template:Unreliable medical source As of 2008 there is no concrete evidence that cannabinoids are effective in improving the symptoms of AD or dementia.[145] Some research in its early stages however looks promising.[146]


Some studies have shown an increased risk of developing AD with environmental factors such the intake of metals, particularly aluminium.[147] The quality of some of these studies has been criticised,[148] and other studies have concluded that there is no relationship between these environmental factors and the development of AD.[149]

While some studies suggest that extremely low frequency electromagnetic fields may increase the risk for Alzheimer's disease,[150] reviewers found that further epidemiological and laboratory investigations of this hypothesis are needed.[151] Smoking is a significant AD risk factor.[152] Systemic markers of the innate immune system are risk factors for late-onset AD.[153]


There is no cure for Alzheimer's disease; available treatments offer relatively small symptomatic benefit but remain palliative in nature. Current treatments can be divided into pharmaceutical, psychosocial and caregiving.


File:Donepezil 1EVE.png

Five medications are currently used to treat the cognitive problems of AD: four are acetylcholinesterase inhibitors (tacrine, rivastigmine, galantamine and donepezil) and the other (memantine) is an NMDA receptor antagonist.[154] The benefit from their use is small.[155][156] No medication has been clearly shown to delay or halt the progression of the disease.

Reduction in the activity of the cholinergic neurons is a well-known feature of Alzheimer's disease.[157] Acetylcholinesterase inhibitors are employed to reduce the rate at which acetylcholine (ACh) is broken down, thereby increasing the concentration of ACh in the brain and combating the loss of ACh caused by the death of cholinergic neurons.[158] There is evidence for the efficacy of these medications in mild to moderate Alzheimer's disease,[159][160] and some evidence for their use in the advanced stage. Only donepezil is approved for treatment of advanced AD dementia.[161] The use of these drugs in mild cognitive impairment has not shown any effect in a delay of the onset of AD.[162] The most common side effects are nausea and vomiting, both of which are linked to cholinergic excess. These side effects arise in approximately 10–20% of users and are mild to moderate in severity. Less common secondary effects include muscle cramps, decreased heart rate (bradycardia), decreased appetite and weight, and increased gastric acid production.[163]

Glutamate is a useful excitatory neurotransmitter of the nervous system, although excessive amounts in the brain can lead to cell death through a process called excitotoxicity which consists of the overstimulation of glutamate receptors. Excitotoxicity occurs not only in Alzheimer's disease, but also in other neurological diseases such as Parkinson's disease and multiple sclerosis.[164] Memantine (brand names Akatinol)[165] is a noncompetitive NMDA receptor antagonist first used as an anti-influenza agent. It acts on the glutamatergic system by blocking NMDA receptors and inhibiting their overstimulation by glutamate.[164] Memantine has been shown to be moderately efficacious in the treatment of moderate to severe Alzheimer's disease. Its effects in the initial stages of AD are unknown.[166] Reported adverse events with memantine are infrequent and mild, including hallucinations, confusion, dizziness, headache and fatigue.[167] The combination of memantine and donepezil has been shown to be "of statistically significant but clinically marginal effectiveness".[168]

Antipsychotic drugs are modestly useful in reducing aggression and psychosis in Alzheimer's disease with behavioural problems, but are associated with serious adverse effects, such as cerebrovascular events, movement difficulties or cognitive decline, that do not permit their routine use.[169][170] When used in the long-term, they have been shown to associate with increased mortality.[170]

Huperzine A while promising, requires further evidence before it use can be recommended.[171]

Psychosocial interventionEdit

See also: Music therapy for Alzheimer's disease

Psychosocial interventions are used as an adjunct to pharmaceutical treatment and can be classified within behaviour-, emotion-, cognition- or stimulation-oriented approaches. Research on efficacy is unavailable and rarely specific to AD, focusing instead on dementia in general.[172]

Behavioural interventions attempt to identify and reduce the antecedents and consequences of problem behaviours. This approach has not shown success in improving overall functioning,[173] but can help to reduce some specific problem behaviours, such as incontinence.[174] There is a lack of high quality data on the effectiveness of these techniques in other behaviour problems such as wandering.[175][176]

Emotion-oriented interventions include reminiscence therapy, validation therapy, supportive psychotherapy, sensory integration, also called snoezelen, and simulated presence therapy. Supportive psychotherapy has received little or no formal scientific study, but some clinicians find it useful in helping mildly impaired people adjust to their illness.[172] Reminiscence therapy (RT) involves the discussion of past experiences individually or in group, many times with the aid of photographs, household items, music and sound recordings, or other familiar items from the past. Although there are few quality studies on the effectiveness of RT, it may be beneficial for cognition and mood.[177] Simulated presence therapy (SPT) is based on attachment theories and involves playing a recording with voices of the closest relatives of the person with Alzheimer's disease. There is partial evidence indicating that SPT may reduce challenging behaviours.[178] Finally, validation therapy is based on acceptance of the reality and personal truth of another's experience, while sensory integration is based on exercises aimed to stimulate senses. There is no evidence to support the usefulness of these therapies.[179][180]

The aim of cognition-oriented treatments, which include reality orientation and cognitive retraining, is the reduction of cognitive deficits. Reality orientation consists in the presentation of information about time, place or person to ease the understanding of the person about its surroundings and his or her place in them. On the other hand cognitive retraining tries to improve impaired capacities by exercitation of mental abilities. Both have shown some efficacy improving cognitive capacities,[181][182] although in some studies these effects were transient and negative effects, such as frustration, have also been reported.[172]

Stimulation-oriented treatments include art, music and pet therapies, exercise, and any other kind of recreational activities. Stimulation has modest support for improving behaviour, mood, and, to a lesser extent, function. Nevertheless, as important as these effects are, the main support for the use of stimulation therapies is the change in the person's routine.[172]


Further information: Caregiving and dementia

Since Alzheimer's has no cure and it gradually renders people incapable of tending for their own needs, caregiving essentially is the treatment and must be carefully managed over the course of the disease.

During the early and moderate stages, modifications to the living environment and lifestyle can increase patient safety and reduce caretaker burden.[183][184] Examples of such modifications are the adherence to simplified routines, the placing of safety locks, the labelling of household items to cue the person with the disease or the use of modified daily life objects.[172][185][186] Patients may also become incapable of feeding themselves, so they require food in smaller pieces or pureed.[187] When swallowing difficulties arise, the use of feeding tubes may be required. In such cases, the medical efficacy and ethics of continuing feeding is an important consideration of the caregivers and family members.[188][189] The use of physical restraints is rarely indicated in any stage of the disease, although there are situations when they are necessary to prevent harm to the person with AD or their caregivers.[172]

As the disease progresses, different medical issues can appear, such as oral and dental disease, pressure ulcers, malnutrition, hygiene problems, or respiratory, skin, or eye infections. Careful management can prevent them, while professional treatment is needed when they do arise.[190][191] During the final stages of the disease, treatment is centred on relieving discomfort until death.[192]

A small recent study in the US concluded that people whose caregivers had a realistic understanding of the prognosis and clinical complications of late dementia were less likely to receive aggressive treatment near the end of life. [193]

Feeding tubesEdit

There is strong evidence that feeding tubes do not help people with advanced Alzheimer's dementia gain weight, regain strength or function, prevent aspiration pneumonias, or improve quality of life.[194][195][196][197]


File:Alzheimer and other dementias world map - DALY - WHO2004.svg

The early stages of Alzheimer's disease are difficult to diagnose. A definitive diagnosis is usually made once cognitive impairment compromises daily living activities, although the person may still be living independently. The symptoms will progress from mild cognitive problems, such as memory loss through increasing stages of cognitive and non-cognitive disturbances, eliminating any possibility of independent living, especially in the late stages of the disease.[26]

Life expectancy of the population with the disease is reduced.[9][198][199] The mean life expectancy following diagnosis is approximately seven years.[9] Fewer than 3% of people live more than fourteen years.[10] Disease features significantly associated with reduced survival are an increased severity of cognitive impairment, decreased functional level, history of falls, and disturbances in the neurological examination. Other coincident diseases such as heart problems, diabetes or history of alcohol abuse are also related with shortened survival.[198][200][201] While the earlier the age at onset the higher the total survival years, life expectancy is particularly reduced when compared to the healthy population among those who are younger.[199] Men have a less favourable survival prognosis than women.[10][202]

The disease is the underlying cause of death in 70% of all cases.[9] Pneumonia and dehydration are the most frequent immediate causes of death, while cancer is a less frequent cause of death than in the general population.[9][202]


Incidence rates
after age 65[203]
Age New affected
per thousand
65–69  3
70–74  6
75–79  9
80–84 23
85–89 40
90–     69

Two main measures are used in epidemiological studies: incidence and prevalence. Incidence is the number of new cases per unit of person–time at risk (usually number of new cases per thousand person–years); while prevalence is the total number of cases of the disease in the population at any given time.

Regarding incidence, cohort longitudinal studies (studies where a disease-free population is followed over the years) provide rates between 10 and 15 per thousand person–years for all dementias and 5–8 for AD,[203][204] which means that half of new dementia cases each year are AD. Advancing age is a primary risk factor for the disease and incidence rates are not equal for all ages: every five years after the age of 65, the risk of acquiring the disease approximately doubles, increasing from 3 to as much as 69 per thousand person years.[203][204] There are also sex differences in the incidence rates, women having a higher risk of developing AD particularly in the population older than 85.[204][205] The risk of dying from Alzheimer’s disease is twenty-six percent higher among the non-Hispanic white population than among the non-Hispanic black population, whereas the Hispanic population has a thirty percent lower risk than the non-Hispanic white population.[206]

Prevalence of AD in populations is dependent upon different factors including incidence and survival. Since the incidence of AD increases with age, it is particularly important to include the mean age of the population of interest. In the United States, Alzheimer prevalence was estimated to be 1.6% in 2000 both overall and in the 65–74 age group, with the rate increasing to 19% in the 75–84 group and to 42% in the greater than 84 group.[207] Prevalence rates in less developed regions are lower.[208] The World Health Organization estimated that in 2005, 0.379% of people worldwide had dementia, and that the prevalence would increase to 0.441% in 2015 and to 0.556% in 2030.[209] Other studies have reached similar conclusions.[208] Another study estimated that in 2006, 0.40% of the world population (range 0.17–0.89%; absolute number 26.6 million, range 11.4–59.4 million) were afflicted by AD, and that the prevalence rate would triple and the absolute number would quadruple by 2050.[3]


File:Auguste D aus Marktbreit.jpg

The ancient Greek and Roman philosophers and physicians associated old age with increasing dementia.[1] It was not until 1901 that German psychiatrist Alois Alzheimer identified the first case of what became known as Alzheimer's disease in a fifty-year-old woman he called Auguste D. He followed her case until she died in 1906, when he first reported publicly on it.[210] During the next five years, eleven similar cases were reported in the medical literature, some of them already using the term Alzheimer's disease.[1] The disease was first described as a distinctive disease by Emil Kraepelin after suppressing some of the clinical (delusions and hallucinations) and pathological features (arteriosclerotic changes) contained in the original report of Auguste D.[211] He included Alzheimer's disease, also named presenile dementia by Kraepelin, as a subtype of senile dementia in the eighth edition of his Textbook of Psychiatry, published on 15 July, 1910.[212]

For most of the 20th century, the diagnosis of Alzheimer's disease was reserved for individuals between the ages of 45 and 65 who developed symptoms of dementia. The terminology changed after 1977 when a conference on AD concluded that the clinical and pathological manifestations of presenile and senile dementia were almost identical, although the authors also added that this did not rule out the possibility that they had different causes.[213] This eventually led to the diagnosis of Alzheimer's disease independently of age.[214] The term senile dementia of the Alzheimer type (SDAT) was used for a time to describe the condition in those over 65, with classical Alzheimer's disease being used for those younger. Eventually, the term Alzheimer's disease was formally adopted in medical nomenclature to describe individuals of all ages with a characteristic common symptom pattern, disease course, and neuropathology.[215]

Notable casesEdit

  • Holy Polish Emperor and King of Poland Charles I was best known who diagnosed with Alzheimer's disease in 1858 after he was voluntary abdication, but that he died in next year at age of 83.
  • United States president Ronald Reagan, who diagnosed with Alzheimer's disease in 1994 after he left office in 1989, he died 10 years later at age of 93 in 2004.

Society and cultureEdit

Social costsEdit

Dementia, and specifically Alzheimer's disease, may be among the most costly diseases for society in Europe and the United States,[18][19] while their cost in other countries such as Argentina,[216] or South Korea,[217] is also high and rising. These costs will probably increase with the ageing of society, becoming an important social problem. AD-associated costs include direct medical costs such as nursing home care, direct nonmedical costs such as in-home day care, and indirect costs such as lost productivity of both patient and caregiver.[19] Numbers vary between studies but dementia costs worldwide have been calculated around $160 billion,[218] while costs of Alzheimer's disease in the United States may be $100 billion each year.[19]

The greatest origin of costs for society is the long-term care by health care professionals and particularly institutionalisation, which corresponds to 2/3 of the total costs for society.[18] The cost of living at home is also very high,[18] especially when informal costs for the family, such as caregiving time and caregiver's lost earnings, are taken into account.[219]

Costs increase with dementia severity and the presence of behavioural disturbances,[220] and are related to the increased caregiving time required for the provision of physical care.[219] Therefore any treatment that slows cognitive decline, delays institutionalisation or reduces caregivers' hours will have economic benefits. Economic evaluations of current treatments have shown positive results.[19]

Caregiving burdenEdit

Further information: Caregiving and dementia

The role of the main caregiver is often taken by the spouse or a close relative.[14] Alzheimer's disease is known for placing a great burden on caregivers which includes social, psychological, physical or economic aspects.[15][16][17] Home care is usually preferred by people with AD and their families.[221] This option also delays or eliminates the need for more professional and costly levels of care.[221][222] Nevertheless two-thirds of nursing home residents have dementias.[172]

Dementia caregivers are subject to high rates of physical and mental disorders.[223] Factors associated with greater psychosocial problems of the primary caregivers include having an affected person at home, the carer being a spouse, demanding behaviours of the cared person such as depression, behavioural disturbances, hallucinations, sleep problems or walking disruptions and social isolation.[224][225] Regarding economic problems, family caregivers often give up time from work to spend 47 hours per week on average with the person with AD, while the costs of caring for them are high. Direct and indirect costs of caring for an Alzheimer's patient average between $18,000 and $77,500 per year in the United States, depending on the study.[14][219]

Cognitive behavioural therapy and the teaching of coping strategies either individually or in group have demonstrated their efficacy in improving caregivers' psychological health.[15][226]

Notable casesEdit

Further information: Alzheimer's in the media
See also: Alzheimer's disease organizations
File:Ronald Reagan Charlton Heston.jpg

As Alzheimer's disease is highly prevalent, many notable people have developed it. Well-known examples are former United States President Ronald Reagan and Irish writer Iris Murdoch, both of whom were the subjects of scientific articles examining how their cognitive capacities deteriorated with the disease.[227][228][229] Other cases include the retired footballer Ferenc Puskás,[230] the former Prime Ministers Harold Wilson (United Kingdom) and Adolfo Suárez (Spain),[231][232] the actress Rita Hayworth,[233] the actor Charlton Heston,[234] the novelist Terry Pratchett,[235] Indian politician George Fernandes,[236] and the 2009 Nobel Prize in Physics recipient Charles K. Kao.[237]

AD has also been portrayed in films such as: Iris (2001), based on John Bayley's memoir of his wife Iris Murdoch;[238] The Notebook (2004), based on Nicholas Sparks' 1996 novel of the same name;[239] A Moment to Remember (2004);Thanmathra (2005);[240] Memories of Tomorrow (Ashita no Kioku) (2006), based on Hiroshi Ogiwara's novel of the same name;[241] Away from Her (2006), based on Alice Munro's short story "The Bear Came over the Mountain".[242] Documentaries on Alzheimer's disease include Malcolm and Barbara: A Love Story (1999) and Malcolm and Barbara: Love's Farewell (2007), both featuring Malcolm Pointon.[243]

Research directionsEdit

Main article: Alzheimer's disease research

Template:As of, the safety and efficacy of more than 400 pharmaceutical treatments had been or were being investigated in 1012 clinical trials worldwide, and approximately a quarter of these compounds are in Phase III trials, the last step prior to review by regulatory agencies.[12]

One area of clinical research is focused on treating the underlying disease pathology. Reduction of beta-amyloid levels is a common target of compounds[244] (such as apomorphine) under investigation. Immunotherapy or vaccination for the amyloid protein is one treatment modality under study.[245] Unlike preventative vaccination, the putative therapy would be used to treat people already diagnosed. It is based upon the concept of training the immune system to recognise, attack, and reverse deposition of amyloid, thereby altering the course of the disease.[246] An example of such a vaccine under investigation was ACC-001,[247][248] although the trials were suspended in 2008.[249] Another similar agent is bapineuzumab, an antibody designed as identical to the naturally induced anti-amyloid antibody.[250] Other approaches are neuroprotective agents, such as AL-108,[251] and metal-protein interaction attenuation agents, such as PBT2.[252] A TNFα receptor fusion protein, etanercept has showed encouraging results.[253]

In 2008, two separate clinical trials showed positive results in modifying the course of disease in mild to moderate AD with methylthioninium chloride (trade name rember), a drug that inhibits tau aggregation,[254][255] and dimebon, an antihistamine.[256] The consecutive phase-III trial of dimebon failed to show positive effects in the primary and secondary endpoints.[257][258][259]

The common herpes simplex virus HSV-1 has been found to colocate with amyloid plaques.[260] This suggested the possibility that AD could be treated or prevented with antiviral medication.[260][261]

Preliminary research on the effects of meditation on retrieving memory and cognitive functions have been encouraging. Limitations of this research can be addressed in future studies with more detailed analyses.[262]

An FDA panel voted unanimously to recommend approval of florbetapir, which is currently used in an investigational study. The imaging agent can help to detect Alzheimer's brain plaques, but will require additional clinical research before it can be made available commercially.[263]

Manned spaceflight may harm the brain of astronauts and accelerate the onset of Alzheimer's disease.[264]


In a person already having dementia, single photon emission computed tomography (SPECT) appears to be superior in differentiating Alzheimer's disease from other possible causes, compared with the usual attempts employing mental testing and medical history analysis.[265] Advances have led to the proposal of new diagnostic criteria.[5][97]

PiB PET remains investigational, but a similar PET scanning radiopharmaceutical called florbetapir, containing the longer-lasting radionuclide fluorine-18, has recently been tested as a diagnostic tool in Alzheimer's disease, and given FDA approval for this use.[266][267]

Amyloid imaging is likely to be used in conjunction with other markers rather than as an alternative.[268] Volumetric MRI can detect changes in the size of brain regions. Measuring those regions that atrophy during the progress of Alzheimer's disease is showing promise as a diagnostic indicator. It may prove less expensive than other imaging methods currently under study.[269]


  1. 1.0 1.1 1.2 Template:Vcite journal
  2. Template:Vcite journal
  3. 3.0 3.1 2006 prevalence estimate:
  4. "What is Alzheimer's disease?". August 2007. Retrieved 21 February 2008.
  5. 5.0 5.1 5.2 5.3 5.4 5.5 5.6 Template:Vcite journal
  6. "Alzheimer's diagnosis of AD". Alzheimer's Research Trust. Retrieved 29 February 2008.
  7. Template:Vcite journal
  8. "About Alzheimer's Disease: Symptoms". National Institute on Aging. Retrieved 28 December 2011.
  9. 9.0 9.1 9.2 9.3 9.4 Template:Vcite journal
  10. 10.0 10.1 10.2 Template:Vcite journal
  11. 11.0 11.1 11.2 Template:Vcite journal
  12. 12.0 12.1 "Clinical Trials. Found 1012 studies with search of: alzheimer". US National Institutes of Health. Retrieved 10 January 2011.
  13. "More research needed on ways to prevent Alzheimer's, panel finds" (PDF). National Institute on Aging. 29 August 2006. Retrieved 29 February 2008.
  14. 14.0 14.1 14.2 "The MetLife study of Alzheimer's disease: The caregiving experience" (PDF). MetLife Mature Market Institute. August 2006. Archived from the original on 8 January 2011. Retrieved 5 February 2011.
  15. 15.0 15.1 15.2 Template:Vcite journal
  16. 16.0 16.1 Template:Vcite journal
  17. 17.0 17.1 Template:Vcite journal
  18. 18.0 18.1 18.2 18.3 Template:Vcite journal
  19. 19.0 19.1 19.2 19.3 19.4 Template:Vcite journal
  20. 20.0 20.1 20.2 Template:Vcite journal
  21. Template:Vcite journal
  22. 22.0 22.1 Template:Vcite journal
  23. Template:Vcite journal
  24. Murray ED, Buttner N, Price BH (2012). "Depression and Psychosis in Neurological Practice". In Bradley WG, Daroff RB, Fenichel GM, Jankovic J. Bradley's neurology in clinical practice. (6th ed.). Philadelphia, PA: Elsevier/Saunders. Template:Citation/identifier.
  25. Template:Vcite journal
  26. 26.00 26.01 26.02 26.03 26.04 26.05 26.06 26.07 26.08 26.09 26.10 26.11 26.12 26.13 26.14 26.15 26.16 26.17 26.18 26.19 26.20 26.21 26.22 Template:Vcite journal
  27. Template:Vcite journal
  28. Template:Vcite journal
  29. 29.0 29.1 Taler V, Phillips NA (July 2008). "Language Performance in Alzheimer's Disease and Mild Cognitive Impairment: a comparative review". J Clin Exp Neuropsychol 30 (5): 501–56. Template:Citation/identifier. Template:Citation/identifier.
  30. 30.0 30.1 30.2 Template:Vcite journal
  31. Template:Vcite journal
  32. Template:Vcite journal
  33. "What We Know Today About Alzheimer's Disease". Alzheimer's Association. Retrieved 1 October 2011. "While scientists know Alzheimer's disease involves progressive brain cell failure, the reason cells fail isn't clear."
  34. 34.0 34.1 34.2 Template:Vcite journal
  35. 35.0 35.1 Template:Vcite journal
  36. 36.0 36.1 Template:Vcite journal
  37. Template:Vcite journal
  38. Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, Stefansson H, Sulem P, Gudbjartsson D, Maloney J, Hoyte K, Gustafson A, Liu Y, Lu Y, Bhangale T, Graham RR, Huttenlocher J, Bjornsdottir G, Andreassen OA, Jönsson EG, Palotie A, Behrens TW, Magnusson OT, Kong A, Thorsteinsdottir U, Watts RJ, Stefansson K. (2 August 2012). "A mutation in APP protects against Alzheimer's disease and age-related cognitive decline.". Nature 488 (7409): 96–9. Template:Citation/identifier.
  39. Template:Vcite journal
  40. 40.0 40.1 Template:Vcite journal
  41. Template:Vcite journal
  42. Template:Vcite journal
  43. Boada M, Antúnez C, Ramírez-Lorca R, Destefano AL, González-Pérez A, Gayán J, López-Arrieta J, Ikram MA, Hernández I, Marín J, Galán JJ, Bis JC, Mauleón A, Rosende-Roca M, Moreno-Rey C, Gudnasson V, Morón FJ, Velasco J, Carrasco JM, Alegret M, Espinosa A, Vinyes G, Lafuente A, Vargas L, Fitzpatrick AL; for the Alzheimer’s Disease Neuroimaging Initiative, Launer LJ, Sáez ME, Vázquez E, Becker JT, López OL, Serrano-Ríos M, Tárraga L, van Duijn CM, Real LM, Seshadri S, Ruiz A (16 July 2013). "ATP5H/KCTD2 locus is associated with Alzheimer's disease risk". Molecular Psychiatry. Template:Citation/identifier. Template:Citation/identifier.
  44. Ghani M, Sato C, Lee JH, Reitz C, Moreno D, Mayeux R, St George-Hyslop P, Rogaeva E (26 August 2013). "Evidence of Recessive Alzheimer Disease Loci in a Caribbean Hispanic Data Set: Genome-wide Survey of Runs of Homozygosity". JAMA Neurol. 70 (10): 1261–7. Template:Citation/identifier. Template:Citation/identifier.
  45. Rhinn H, Fujita R, Qiang L, Cheng R, Lee JH, Abeliovich A (1 August 2013). "Integrative genomics identifies APOE ε4 effectors in Alzheimer's disease". Nature 500 (7460): 45–50. Template:Citation/identifier. Template:Citation/identifier.
  46. Jonsson, Thorlakur; Stefansson, Hreinn; Steinberg, Stacy; Jonsdottir, Ingileif; Jonsson, Palmi V; Snaedal, Jon; Bjornsson, Sigurbjorn; Huttenlocher, Johanna et al. (2012). "Variant of TREM2 associated with the risk of Alzheimer's disease". New England Journal of Medicine 368 (2): 107–16. Template:Citation/identifier. Template:Citation/identifier. Template:Citation/identifier.
  47. Guerreiro, Rita; Wojtas, Aleksandra; Bras, Jose; Carrasquillo, Minerva; Rogaeva, Ekaterina; Majounie, Elisa; Cruchaga, Carlos; Sassi, Celeste et al. (2012). "TREM2 variants in Alzheimer's disease". New England Journal of Medicine 368 (2): 117–27. Template:Citation/identifier. Template:Citation/identifier. Template:Citation/identifier.
  48. Template:Vcite journal
  49. Template:Vcite journal
  50. 50.0 50.1 Template:Vcite journal
  51. Template:Vcite journal
  52. 52.0 52.1 Template:Vcite journal
  53. Template:Vcite journal
  54. Template:Vcite journal
  55. Template:Vcite journal
  56. Transgenic mice:
  57. Template:Vcite journal
  58. Template:Vcite journal
  59. Template:Vcite journal
  60. 60.0 60.1 Template:Vcite journal
  61. Template:Vcite journal
  62. Template:Vcite journal
  63. Template:Vcite journal
  64. Template:Vcite journal
  65. Brewer, George J. (March 2012). "Copper excess, zinc deficiency, and cognition loss in Alzheimer's disease". BioFactors 38 (2): 107–113. Template:Citation/identifier. Template:Citation/identifier.
  66. Bartzokis G (August 2011). "Alzheimer's Disease as Homeostatic Responses to Age-related Myelin Breakdown". Neurobiol. Aging 32 (8): 1341–71. Template:Citation/identifier. Template:Citation/identifier. Template:Citation/identifier.
  67. Bartzokis G, Lu PH, Mintz J (December 2004). "Quantifying Age-Related Myelin Breakdown with MRI: Novel Therapeutic Targets for Preventing Cognitive Decline and Alzheimer's Disease". J. Alzheimers Dis. 6 (6 Suppl): S53–9. Template:Citation/identifier.
  68. Bartzokis G, Lu PH, Mintz J (April 2007). "Human Brain Myelination and Beta-amyloid Deposition in Alzheimer's Disease". Alzheimers Dement 3 (2): 122–5. Template:Citation/identifier. Template:Citation/identifier. Template:Citation/identifier.
  69. Su B, Wang X, Nunomura A, et al. (December 2008). "Oxidative Stress Signaling in Alzheimer's Disease". Curr Alzheimer Res 5 (6): 525–32. Template:Citation/identifier. Template:Citation/identifier. Template:Citation/identifier.
  70. Kastenholz B, Garfin DE, Horst J, Nagel KA (2009). "Plant Metal Chaperones: A Novel Perspective in Dementia Therapy". Amyloid 16 (2): 81–3. Template:Citation/identifier. Template:Citation/identifier.
  71. Pohanka M (2013). "Alzheimer´s Disease and Oxidative Stress: A Review". Curr. Med. Chem. 21 (3): 356–64. Template:Citation/identifier. Template:Citation/identifier.
  72. 72.0 72.1 72.2 Heneka MT, Nadrigny F, Regen T, Martinez-Hernandez A, Dumitrescu-Ozimek L, Terwel D, Jardanhazi-Kurutz D, Walter J, Kirchhoff F, Hanisch UK, Kummer MP. (2010). Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine. Proceedings of the National Academy of Sciences of the United States of America 107:6058–6063 Template:Doi PMID 20231476
  73. Paula Valencia Moulton and Wei Yang (2012). "Air Pollution, Oxidative Stress, and Alzheimer's Disease". Journal of Environmental and Public Health 2012: 472751. Template:Citation/identifier. Template:Citation/identifier.
  74. Braak H, Del Tredici K. (December 2012). "Where, when, and in what form does sporadic Alzheimer's disease begin?". Current Opinion in Neurology 25 (Pt 6): 708–14. Template:Citation/identifier. Template:Citation/identifier.
  75. Desikan RS, Cabral HJ, Hess CP, et al. (August 2009). "Automated MRI Measures Identify Individuals with Mild Cognitive Impairment and Alzheimer's Disease". Brain 132 (Pt 8): 2048–57. Template:Citation/identifier. Template:Citation/identifier. Template:Citation/identifier.
  76. Template:Vcite journal
  77. Template:Vcite journal
  78. Template:Vcite journal
  79. Template:Vcite journal
  80. Template:Vcite journal
  81. Template:Vcite journal
  82. Template:Vcite journal
  83. Template:Vcite journal
  84. Template:Vcite journal
  85. Template:Vcite journal
  86. Template:Vcite journal
  87. Template:Vcite journal
  88. Template:Vcite journal
  89. Template:Vcite journal
  90. Template:Vcite journal
  91. Template:Vcite journal
  92. Template:Vcite journal
  93. Template:Vcite journal
  94. (PDF) Dementia: Quick Reference Guide. London: (UK) National Institute for Health and Clinical Excellence. November 2006. Template:Citation/identifier. Archived from the original on 27 February 2008. Retrieved 22 February 2008.
  95. 95.0 95.1 Template:Vcite journal
  96. 96.0 96.1 Template:Vcite journal
  97. 97.0 97.1 Template:Vcite journal
  98. Template:Vcite journal
  99. American Psychiatric Association (2000). Diagnostic and statistical manual of mental disorders: DSM-IV-TR (4th Edition Text Revision ed.). Washington, DC: American Psychiatric Association. Template:Citation/identifier.
  100. Template:Vcite journal
  101. Template:Vcite journal
  102. Template:Vcite journal
  103. Template:Vcite journal
  104. Template:Vcite journal
  105. Template:Vcite journal
  106. Template:Vcite journal
  107. Template:Vcite journal
  108. Template:Vcite journal
  109. Chong, M; Sahadevan, S (1 Sep 2005). "Preclinical Alzheimer's disease: diagnosis and prediction of progression.". Lancet Neurology (The Lancet) 4 (9): 576–9. Template:Citation/identifier. Template:Citation/identifier. Retrieved 7 April 2014.
  110. Template:Vcite journal
  111. 111.0 111.1 111.2 Template:Vcite journal
  112. Prevention recommendations not supported:
  113. Template:Vcite journal
  114. Template:Vcite journal
  115. Template:Vcite journal
  116. Template:Vcite journal
  117. Template:Vcite journal
  118. 118.0 118.1 118.2 Template:Vcite journal
  119. Lehrer S. Nasal NSAIDs for Alzheimer's Disease. Am J Alzheimers Dis Other Demen. 2014 Jan 9. [Epub ahead of print]. Template:Citation/identifier.
  120. Marjoribanks J, Farquhar C, Roberts H, Lethaby A (2012). Farquhar, Cindy. ed. "Long term hormone therapy for perimenopausal and postmenopausal women". Cochrane Database of Systematic Reviews 7: CD004143. Template:Citation/identifier. Template:Citation/identifier.
  121. 121.0 121.1 Template:Cite pmid
  122. 122.0 122.1 Template:Vcite journal
  123. Neergaard, Lauran (19 February 2011). "Speaking 2 Languages May Delay Getting Alzheimer's". Associated Press. The Denver Post.
  124. Sofi, F; Macchi, C; Abbate, R; Gensini, GF; Casini, A (2010). "Effectiveness of the Mediterranean diet: can it help delay or prevent Alzheimer's disease?". Journal of Alzheimer's disease : JAD 20 (3): 795–801. Template:Citation/identifier. Template:Citation/identifier.
  125. 125.0 125.1 Template:Vcite journal
  126. Solfrizzi, V; Panza, F; Frisardi, V; Seripa, D; Logroscino, G; Imbimbo, BP; Pilotto, A (May 2011). "Diet and Alzheimer's disease risk factors or prevention: the current evidence.". Expert Review of Neurotherapeutics 11 (5): 677–708. Template:Citation/identifier. Template:Citation/identifier.
  127. Kanoski, SE; Davidson, TL (18 April 2011). "Western diet consumption and cognitive impairment: links to hippocampal dysfunction and obesity". Physiology & behavior 103 (1): 59–68. Template:Citation/identifier. Template:Citation/identifier. Template:Citation/identifier.
  128. Template:Vcite journal
  129. Santos C, Costa J, Santos J, Vaz-Carneiro A, Lunet N (2010). "Caffeine intake and dementia: systematic review and meta-analysis". J. Alzheimers Dis. 20 Suppl 1: S187–204. Template:Citation/identifier. Template:Citation/identifier.
  130. Nehlig, Astrid (July 2012). "The neuroprotective effects of cocoa flavanol and its influence on cognitive performance". British Journal of Clinical Pharmacology 75 (3): n/a–n/a. Template:Citation/identifier. Template:Citation/identifier.
  131. Stoclet, JC; Schini-Kerth, V (March 2011). "[Dietary flavonoids and human health].". Annales pharmaceutiques francaises 69 (2): 78–90. Template:Citation/identifier. Template:Citation/identifier.
  132. Ono, K; Yamada, M (April 2012). "Vitamin A and Alzheimer's disease". Geriatrics & gerontology international 12 (2): 180–8. Template:Citation/identifier. Template:Citation/identifier.
  133. Lerner, AJ; Gustaw-Rothenberg, K; Smyth, S; Casadesus, G (Mar–Apr 2012). "Retinoids for treatment of Alzheimer's disease.". BioFactors (Oxford, England) 38 (2): 84–9. Template:Citation/identifier. Template:Citation/identifier.
  134. Heo, JH; Hyon-Lee,; Lee, KM (March 2013). "The possible role of antioxidant vitamin C in Alzheimer's disease treatment and prevention". American journal of Alzheimer's disease and other dementias 28 (2): 120–5. Template:Citation/identifier. Template:Citation/identifier.
  135. 135.0 135.1 135.2 Template:Vcite journal
  136. Template:Vcite journal
  137. Loef, M; Schrauzer, GN; Walach, H (2011). "Selenium and Alzheimer's disease: a systematic review". Journal of Alzheimer's disease : JAD 26 (1): 81–104. Template:Citation/identifier. Template:Citation/identifier.
  138. Loef, Martin; von Stillfried, Nikolaus; Walach, Harald (1 September 2012). "Zinc diet and Alzheimer's disease: a systematic review". Nutritional Neuroscience 15 (5): 2–12. Template:Citation/identifier. Template:Citation/identifier.
  139. Template:Vcite journal
  140. Template:Vcite journal
  141. Cunnane, SC; Chouinard-Watkins, R; Castellano, CA; Barberger-Gateau, P (January 2013). "Docosahexaenoic acid homeostasis, brain aging and Alzheimer's disease: Can we reconcile the evidence?". Prostaglandins, leukotrienes, and essential fatty acids 88 (1): 61–70. Template:Citation/identifier. Template:Citation/identifier.
  142. Hamaguchi T, Ono K, Yamada M (October 2010). "REVIEW: Curcumin and Alzheimer's disease". CNS Neurosci Ther 16 (5): 285–97. Template:Citation/identifier. Template:Citation/identifier.
  143. Template:Vcite journal
  144. Template:Vcite journal
  145. Krishnan S, Cairns R, Howard R (2009). Krishnan, Sarada. ed. "Cannabinoids for the treatment of dementia". Cochrane Database of Systematic Reviews (2): CD007204. Template:Citation/identifier. Template:Citation/identifier.
  146. Template:Vcite journal
  147. Template:Vcite journal
  148. Template:Vcite journal
  149. Template:Vcite journal
  150. Kheifets L, Bowman JD, Checkoway H, et al. (February 2009). "Future needs of occupational epidemiology of extremely low frequency electric and magnetic fields: review and recommendations". Occup Environ Med 66 (2): 72–80. Template:Citation/identifier. Template:Citation/identifier.
  151. Template:Vcite journal
  152. Template:Vcite journal
  153. Template:Vcite journal
  154. Pohanka, M (2011). "Cholinesterases, a target of pharmacology and toxicology". Biomedical Papers Olomouc 155 (3): 219–229. Template:Citation/identifier. Template:Citation/identifier.
  155. Commission de la transparence (June 2012). "Médicaments de la maladie d'Alzheimer : à éviter [Drugs for Alzheimer's disease: best avoided. No therapeutic advantage]". Prescrire Int 21 (128): 150. Template:Citation/identifier.
  156. Birks, J; Harvey, RJ (25 January 2006). Birks, Jacqueline. ed. "Donepezil for dementia due to Alzheimer's disease.". Cochrane Database of Systematic Reviews (1): CD001190. Template:Citation/identifier. Template:Citation/identifier.
  157. Geula C, Mesulam MM (1995). "Cholinesterases and the pathology of Alzheimer disease". Alzheimer Dis Assoc Disord 9 Suppl 2: 23–28. Template:Citation/identifier. Template:Citation/identifier.
  158. Stahl SM (2000). "The new cholinesterase inhibitors for Alzheimer's disease, part 2: illustrating their mechanisms of action". J Clin Psychiatry 61 (11): 813–814. Template:Citation/identifier. Template:Citation/identifier.
  159. Birks J (2006). Birks, Jacqueline. ed. "Cholinesterase inhibitors for Alzheimer's disease". Cochrane Database of Systematic Reviews (1): CD005593. Template:Citation/identifier. Template:Citation/identifier.
  160. Birks J, Grimley Evans J, Iakovidou V, Tsolaki M, Holt FE (15 April 2009). Birks, Jacqueline. ed. "Rivastigmine for Alzheimer's disease". Cochrane Database of Systematic Reviews (2): CD001191. Template:Citation/identifier. Template:Citation/identifier.
  161. Birks J, Harvey RJ (25 January 2006). Birks, Jacqueline. ed. "Donepezil for dementia due to Alzheimer's disease". Cochrane Database of Systematic Reviews (1): CD001190. Template:Citation/identifier. Template:Citation/identifier.
  162. Raschetti R, Albanese E, Vanacore N, Maggini M (2007). "Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials". PLOS Medicine 4 (11): e338. Template:Citation/identifier. Template:Citation/identifier. Template:Citation/identifier.
  163. Birks J (2006). Birks, Jacqueline. ed. "Cholinesterase inhibitors for Alzheimer's disease". Cochrane Database of Systematic Reviews (1): CD005593. Template:Citation/identifier. Template:Citation/identifier.
  164. 164.0 164.1 Lipton SA (2006). "Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond". Nature Reviews Drug Discovery 5 (2): 160–170. Template:Citation/identifier. Template:Citation/identifier.
  165. "Memantine". US National Library of Medicine (Medline). 4 January 2004. Archived from the original on 22 February 2010. Retrieved 3 February 2010.
  166. Template:Vcite journal
  167. "Namenda prescribing information" (PDF). Forest Pharmaceuticals. Archived from the original on 27 February 2008. Retrieved 19 February 2008. (primary source)
  168. Raina P; Santaguida P; Ismaila A et al. (2008). "Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline". Annals of Internal Medicine 148 (5): 379–397. Template:Citation/identifier. Template:Citation/identifier.
  169. Antipsychotics use:
  170. 170.0 170.1 Ballard C, Hanney ML, Theodoulou M, Douglas S, McShane R, Kossakowski K, Gill R, Juszczak E, Yu L-M, Jacoby R (9 January 2009). "The Dementia Antipsychotic Withdrawal Trial (DART-AD): Long-term Follow-up of a Randomised Placebo-controlled Trial". Lancet Neurology 8 (2): 151–7. Template:Citation/identifier. Template:Citation/identifier. Lay summary.
  171. Li J, Wu HM, Zhou RL, Liu GJ, Dong BR (2008). Wu, Hong Mei. ed. "Huperzine A for Alzheimer's disease". Cochrane Database of Systematic Reviews (2): CD005592. Template:Citation/identifier. Template:Citation/identifier.
  172. 172.0 172.1 172.2 172.3 172.4 172.5 172.6 APA Work Group on Alzheimer's Disease and other, Dementias; Rabins, PV; Blacker, D; Rovner, BW; Rummans, T; Schneider, LS; Tariot, PN; Blass, DM et al. (December 2007). "American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias". The American Journal of Psychiatry 164 (12 Suppl): 5–56. Template:Citation/identifier.
  173. Bottino CM; Carvalho IA; Alvarez AM et al. (2005). "Cognitive rehabilitation combined with drug treatment in Alzheimer's disease patients: a pilot study". Clin Rehabil 19 (8): 861–869. Template:Citation/identifier. Template:Citation/identifier.
  174. Doody RS, Stevens JC, Beck C et al. (2001). "Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology". Neurology 56 (9): 1154–1166. Template:Citation/identifier. Template:Citation/identifier.
  175. Hermans DG, Htay UH, McShane R (2007). Htay, U Hla. ed. "Non-pharmacological interventions for wandering of people with dementia in the domestic setting". Cochrane Database of Systematic Reviews (1): CD005994. Template:Citation/identifier. Template:Citation/identifier.
  176. Template:Vcite journal
  177. Woods B, Spector A, Jones C, Orrell M, Davies S (2005). Woods, Bob. ed. "Reminiscence therapy for dementia". Cochrane Database of Systematic Reviews (2): CD001120. Template:Citation/identifier. Template:Citation/identifier.
  178. Zetteler J (November 2008). "Effectiveness of simulated presence therapy for individuals with dementia: a systematic review and meta-analysis". Aging Ment Health 12 (6): 779–85. Template:Citation/identifier. Template:Citation/identifier.
  179. Neal M, Briggs M (2003). Neal, Martin. ed. "Validation therapy for dementia". Cochrane Database of Systematic Reviews (3): CD001394. Template:Citation/identifier. Template:Citation/identifier.
  180. Chung JCC, Lai CKY (2002). Chung, Jenny CC. ed. "Snoezelen for dementia". Cochrane Database of Systematic Reviews (4): CD003152. Template:Citation/identifier. Template:Citation/identifier. (up to date as of 2009)
  181. Spector A, Orrell M, Davies S, Woods B (2000). Spector, Aimee E. ed. "Withdrawn: reality orientation for dementia". Cochrane Database of Systematic Reviews (3): CD001119. Template:Citation/identifier. Template:Citation/identifier.
  182. Template:Vcite journal
  183. Template:Vcite journal
  184. Template:Vcite journal
  185. "Treating Behavioral and Psychiatric Symptoms". Alzheimer's Association. 2006. Archived from the original on 25 September 2006. Retrieved 25 September 2006.
  186. Template:Vcite journal
  187. Dudek, Susan G. (2007). Nutrition Essentials for Nursing Practice. Hagerstown, Maryland: Lippincott Williams & Wilkins. p. 360. Template:Citation/identifier. Retrieved 19 August 2008.
  188. Template:Vcite journal
  189. Template:Vcite journal
  190. Template:Vcite journal
  191. Medical issues:
  192. Template:Vcite journal
  193. Template:Vcite journal
  194. Template:Vcite journal
  195. Template:Vcite journal
  196. Template:Vcite journal
  197. "Feeding Tubes in Patients with Severe Dementia". 15 April 2002. Retrieved 16 June 2011.
  198. 198.0 198.1 Template:Vcite journal
  199. 199.0 199.1 Template:Vcite journal
  200. Template:Vcite journal
  201. Template:Vcite journal
  202. 202.0 202.1 Template:Vcite journal
  203. 203.0 203.1 203.2 Template:Vcite journal
  204. 204.0 204.1 204.2 Template:Vcite journal
  205. Template:Vcite journal
  206. Tejada-Vera, B. (2013). Mortality from Alzheimer’s Disease in the United States: Data for 2000 and 2010. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics.
  207. 2000 U.S. estimates:
  208. 208.0 208.1 Template:Vcite journal
  209. World Health Organization (2006). Neurological Disorders: Public Health Challenges. Switzerland: World Health Organization. pp. 204–207. Template:Citation/identifier.
  210. Auguste D.:
  211. Template:Vcite journal
  212. Kraepelin Emil, Diefendorf A. Ross (translated by) (17 January 2007). Clinical Psychiatry: A Textbook For Students And Physicians (Reprint). Kessinger Publishing. p. 568. Template:Citation/identifier.
  213. Katzman Robert, Terry Robert D, Bick Katherine L (editors) (1978). Alzheimer's Disease: Senile Dementia and Related Disorders. New York: Raven Press. p. 595. Template:Citation/identifier.
  214. Template:Vcite journal
  215. Template:Vcite journal
  216. Template:Vcite journal
  217. Template:Vcite journal
  218. Template:Vcite journal
  219. 219.0 219.1 219.2 Template:Vcite journal
  220. Template:Vcite journal
  221. 221.0 221.1 Template:Vcite journal
  222. Template:Vcite journal
  223. Template:Vcite journal
  224. Template:Vcite journal
  225. Template:Vcite journal
  226. Template:Vcite journal
  227. Template:Vcite journal
  228. Template:Vcite journal
  229. Template:Vcite journal
  230. "Hungary Legend Puskas Dies at 79". BBC News. 17 November 2006. Retrieved 25 January 2008.
  231. "Prime Ministers in History: Harold Wilson". London: 10 Downing Street. Archived from the original on 25 August 2008. Retrieved 18 August 2008.
  232. "Mi padre no reconoció al Rey pero notó el cariño". Madrid: El País. 2008. Retrieved 1 October 2008.
  233. "Chicago Rita Hayworth Gala". Alzheimer's Association. 2007. Retrieved 3 February 2010.
  234. "Charlton Heston has Alzheimer's Symptoms". CNN. 9 August 2002. Archived from the original on 1 February 2008. Retrieved 25 January 2008.
  235. Pauli Michelle (12 December 2007). "Pratchett Announces He Has Alzheimer's". London: Guardian News and Media. Archived from the original on 29 September 2008. Retrieved 18 August 2008.
  236. "George Fernandes Being treated for Alzheimer's by Yoga Guru Ramdev". DNA. 19 January 2010. Archived from the original on 22 January 2010. Retrieved 19 January 2010.
  237. "Nobel Winner Kao Coping with Fame and Alzheimer's". China Daily. 9 October 2009. Archived from the original on 24 January 2011. Retrieved 6 February 2011.
  238. Bayley John (2000). Iris: A Memoir of Iris Murdoch. London: Abacus. Template:Citation/identifier. Template:Citation/identifier.
  239. Sparks Nicholas (1996). The notebook. Thorndike, Maine: Thorndike Press. p. 268. Template:Citation/identifier.
  240. "Thanmathra". Retrieved 24 January 2008.
  241. Ogiwara Hiroshi (2004) (in Template:Jp icon). Ashita no Kioku. Tōkyō: Kōbunsha. Template:Citation/identifier. Template:Citation/identifier.
  242. Munro Alice (2001). Hateship, Friendship, Courtship, Loveship, Marriage: Stories. New York: A.A. Knopf. Template:Citation/identifier. Template:Citation/identifier.
  243. Malcolm and Barbara:
  244. Template:Vcite journal
  245. Template:Vcite journal
  246. Vaccination:
  247. "Study Evaluating ACC-001 in Mild to Moderate Alzheimers Disease Subjects". Clinical Trial. US National Institutes of Health. 11 March 2008. Retrieved 5 June 2008.
  248. "Study Evaluating Safety, Tolerability, and Immunogenicity of ACC-001 in Subjects with Alzheimer's Disease". US National Institutes of Health. Retrieved 5 June 2008.
  249. "Alzheimer's Disease Vaccine Trial Suspended on Safety Concern". Medpage Today. 18 April 2008. Retrieved 14 June 2008.
  250. "Bapineuzumab in Patients with Mild to Moderate Alzheimer's Disease/ Apo_e4 Non-carriers" (Clinical Trial). US National Institutes of Health. 29 February 2008. Archived from the original on 22 March 2008. Retrieved 23 March 2008.
  251. "Safety, Tolerability and Efficacy Study to Evaluate Subjects with Mild Cognitive Impairment" (Clinical Trial). US National Institutes of Health. 11 March 2008. Retrieved 23 March 2008.
  252. "Study Evaluating the Safety, Tolerability and Efficacy of PBT2 in Patients with Early Alzheimer's Disease" (Clinical Trial). US National Institutes of Health. 13 January 2008. Retrieved 23 March 2008.
  253. Etanercept research:
  254. Template:Vcite journal
  255. Template:Vcite journal
  256. Template:Vcite journal
  257. Bezprozvanny I (October 2010). "The Rise and fall of Dimebon". Drug News Perspect. 23 (8): 518–23. Template:Citation/identifier. Template:Citation/identifier.
  258. Template:Cite press release
  259. Wendler A, Wehling M (2012). "Translatability scoring in drug development: eight case studies". Journal of Translational Medicine 10 (10): 39. Template:Citation/identifier.
  260. 260.0 260.1 Martin C, Solís L, Concha MI, Otth C (June 2011). "Herpes simplex virus tipo 1 como factor de riesgo asociado con la enfermedad de Alzheimer [Herpes Simplex Virus Type 1 as Risk Factor Associated to Alzheimer Disease]" (in Spanish). Rev Med Chil 139 (6): 779–86. Template:Citation/identifier. Template:Citation/identifier.
  261. Template:Vcite journal
  262. Template:Vcite journal
  263. Template:Vcite journal
  264. Cherry, Jonathan D.; Frost, Jeffrey L.; Lemere, Cynthia A.; Williams, Jacqueline P.; Olschowka, John A.; O'Banion, M. Kerry; o’Banion, M. Kerry (2012). Feinstein, Douglas L. ed. "Galactic Cosmic Radiation Leads to Cognitive Impairment and Increased Aβ Plaque Accumulation in a Mouse Model of Alzheimer's Disease". Plos One 7 (12): e53275. Template:Citation/identifier. Retrieved 7 January 2013.
  265. Template:Vcite journal
  266. Template:Vcite journal
  267. Leung K (8 April 2010). "(E)-4-(2-(6-(2-(2-(2-(18F-fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methyl benzenamine [[18F]AV-45] ]"]. Molecular Imaging and Contrast Agent Database. Retrieved 24 June 2010.
  268. Template:Vcite journal
  269. Template:Vcite journal

Further readingEdit